Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Recurrent Ovarian Cancer”

250 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 250 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03949283
What this trial is testing

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Who this might be right for
Recurrent Ovarian CarcinomaPlatinum-resistant Ovarian Cancer
Cordgenics, LLC 150
Testing effectiveness (Phase 2)Study completedNCT03026062
What this trial is testing

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)UnknownNCT04720807
What this trial is testing

Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07273396
What this trial is testing

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal Neoplasms
Seoul National University Hospital 53
Testing effectiveness (Phase 2)Ended earlyNCT00055432
What this trial is testing

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Looking for participantsNCT06522828
What this trial is testing

Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Who this might be right for
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT02440425
What this trial is testing

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute 42
Early research (Phase 1)Study completedNCT02028117
What this trial is testing

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients

Who this might be right for
Recurrent Platinum Resistant Ovarian Cancer
Akamis Bio 38
Testing effectiveness (Phase 2)Study completedNCT00087087
What this trial is testing

Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group 51
Testing effectiveness (Phase 2)Study completedNCT02759588
What this trial is testing

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CarcinomatosisFallopian Tube Cancer
Genelux Corporation 46
Testing effectiveness (Phase 2)Looking for participantsNCT04518501
What this trial is testing

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Who this might be right for
Efficacy and Safety
Xing Xie 50
Early research (Phase 1)Study completedNCT03213964
What this trial is testing

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota 10
Early research (Phase 1)Not Yet RecruitingNCT07462468
What this trial is testing

Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
WestVac Biopharma Co., Ltd. 36
Early research (Phase 1)Study completedNCT03639246
What this trial is testing

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Aravive, Inc. 53
Early research (Phase 1)Study completedNCT02751918
What this trial is testing

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Who this might be right for
Ovarian Neoplasms
Bayer 65
Testing effectiveness (Phase 2)Study completedNCT02312245
What this trial is testing

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Mayo Clinic 13
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Testing effectiveness (Phase 2)UnknownNCT03539328
What this trial is testing

Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 138
Testing effectiveness (Phase 2)UnknownNCT05475184
What this trial is testing

Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Who this might be right for
Ovarian Cancer
Onconic Therapeutics Inc. 58
Early research (Phase 1)Looking for participantsNCT06515613
What this trial is testing

CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Who this might be right for
Platinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer
Context Therapeutics Inc. 156
Next Page